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Ask any patient with Irritable Bowel Syndrome (IBS) when their condition began and 
most will struggle to answer but the occasional patient will cite a specific date, saying “ I 
was fine until..”.  Such patients who relate onset of their IBS to an episode of infectious 
gastroenteritis appear to be rather different from the others, or are they?  As the current 
review1 shows this has been a very active area of research whose implications are both 
clinical, mechanistic and therapeutic.   
Clinically it is important to recognise this condition to provide the patients with a rational 
explanation for symptoms and to reassure them that the prognosis is relatively benign 
with recovery rates of around one quarter by 1 year 2 and one half by 6-8 years3;4. 
Mechanistically  it offers important opportunities to understand the causation of IBS and 
has stimulated a wealth of research focused on features associated with infection 
including impaired barrier function, immune activation and altered microbiota. The 
therapeutic implications will be discussed in the second half of this commentary. 
The authors report that the incidence of PI-IBS is highly variable worldwide. We should 
perhaps not be surprised, since the infecting pathogens have evolved different strategies 
to overcome host defences.  Some, like Vibrio cholera, secrete a toxin which binds to a 
specific receptor, ganglioside GM1, causing chloride secretion from enterocytes greatly 
amplified by serotonin (5-HT) released from enteroendocrine cells (EEC). This causes 
profuse intestinal secretion and diarrhoea without much inflammation, in contrast  
Shigella flexneri causes extensive immune activation and  ulceration followed by 
increases in substance P and 5-HT positive nerve fibres along with mast cells, 
particularly those surrounded by enteric nerves, changes which are more prominent in 
patients that develop PI-IBS 5. Campylobacter jejuni, one of the commonest causes of 
PI-IBS in Europe, also causes a striking increase in gut permeability with associated 
increase in the proportion of EEC which stain for 5-HT along with evidence of long lasting 
immune activation 6. The nature of the pathogen influences the risk for developing PI-
IBS, the hazard ratio being 4.3 for E coli , 2.9 and 2.5 for C. jejuni and Salmonella spp. 
respectively and just 2.2 for viral gastroenteritis 7. This is in keeping with the lesser 
mucosal damage8 and  typically more rapid recovery after viral enteritis 9. The 
importance of pathogen toxicity is best seen by comparing within a single species such 
as C jejuni where it can be seen that the expression of a cytotoxin increases the risk of 
developing persistent bowel dysfunction 10. 
Giardiasis differs from the above, being a protozoan which affects predominantly the 
upper small bowel 11 while C jejuni cause ileal and colonic ulceration. While C jejuni 
increases  5-HT containing enteroendocrine cells Giardia decreases them but causes an 
increase in cholecystokin (CCK) containing cells12. While both types of infection are 
associated with PI-IBS, Giardia is associated with a much higher rate of postinfectious 
functional dyspepsia, being 25.9% after 3 years 13 compared to just 13% 1 year after 
Salmonellosis 14. This may relate to the higher postprandial CCK levels which correlate 
with dyspepsia scores12. 
 
Host immune status is important with older age protecting against infection15 and also 
PI-IBS 16, possibly reflecting greater immunity gathered over a longer lifetime or less 
hygienic conditions when they were young which may increase the risk of PI-IBS 2. 
Given this marked variability in initial insult and host response it is perhaps not 
surprising that PI-IBS is, like other sorts of IBS, heterogeneous both in its symptoms 
and underlying mechanisms. Indeed perhaps the greatest discovery of the last decade 
has been that PI-IBS is remarkably similar to other sorts of IBS, both in the importance 
of a psychological predisposition 7, as well as the changes in the gut including immune 
activation, impaired barrier function and altered serotonin metabolism. 
This raises the important issue of how much of all IBS is post-infectious? One small early 
study reported that the proportion ranged from 6-17% 17, a figure similar to the 13.3% 
reported in a recent  much larger survey2.   
One key question remains, have these insights lead to specific therapies targeted at 
underlying mechanisms rather than the current symptom directed therapies?  The 
observations of immune activation in PI-IBS encouraged a small pilot study of 
prednisolone in PI-IBS which however showed no benefit 18.  An RCT of the anti-
inflammatory agent mesalazine in IBS-D showed no benefit overall, however post hoc 
analysis showed that a small subgroup  with PI-IBS appeared to respond 19. 
Furthermore, open label treatment of E. coli O147 infection with mesalazine appeared to 
reduce the risk of developing PI-IBS20 but this needs confirming by RCT.  Against this 
small pilot  study of mesalazine in PI-IBS failed to show any difference from placebo 
though it was undoubtedly underpowered20;21  
More encouragingly Keating et al showed that Trichinella infection in mice was followed 
by increased 5-HT availability in the small intestine and visceral hypersensitivity which 
could be blocked by a 5-HT receptor antagonist, ondansetron 22. This and  evidence that  
PI-IBS patients have exaggerated postprandial 5-HT release encouraged a randomised 
placebo controlled trial (RCT) of ondansetron in IBS with diarrhoea (IBS-D) which 
showed relief of IBS symptoms, particularly urgency 23. Small intestinal bacterial 
overgrowth (SIBO) has been shown in rodent models of PI-IBS after Campylobacter 
infection 24and recent studies in India have suggested that PI-IBS may overlap with 
tropical sprue in which SIBO is common25.  Trials with rifaximin targeting SIBO have 
shown a benefit in about 1 in 11 of IBS-D patients.  
As can be seen, most of the literature to date on PI-IBS has been descriptive, what is 
now needed ( see Figure 1) are large randomised trials in PI-IBS of specific treatments 
in which participants are subdivided according to  the underlying mechanisms. The 
response of each subgroup will allow more accurate definition of what is the main driver 
of symptoms and what is mere epiphenomena. Only then will we achieve the precision 
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